After Danaher acquired more than 99% of the shares of Vision Systems in January 2007, Leica Microsystems started integrating Vision BioSystems with its own sectioning and specimen processing business
This integration has led to the formation of a new division of Leica Microsystems The biosystems division will operate alongside Leica Microsystems's other three customer segmented divisions that serve industrial, life science research, and surgical customers.
Combining the product ranges of the two former businesses creates the most comprehensive product portfolio for histo-pathology in the market.
Leica Microsystems biosystems division is the only source to offer instruments for the entire histo-pathology process, as well as the Novocastra range of antibodies and reagents.
The key focus of the division will be to develop innovative, automated systems to improve productivity and enhance quality for customers.
"The combined expertise of these two businesses located at sites in Germany, Australia, and the UK has created the most powerful force in the development of histo-pathology solutions worldwide," emphasises Anne De Greef-Safft, biosystems division president.
The existing product factories in Melbourne, Australia, and Newcastle, UK, together with the German site in Nussloch will continue manufacturing for the division.
